Systems and methods for transvenous lead implantation

• US 8,000,810 B2
• Filed: 03/20/2007
• Issued: 08/16/2011
• Est. Priority Date: 03/20/2007
• Status: Expired due to Fees

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Desai, Shrojalkumar M., Reddy, G. Shantanu
• Primary Examiner(s): Layno; Carl H
• Assistant Examiner(s): SARCIONE, JESSICA LYNN
• Application Number:
  US11/688,699
• Publication Number:
  US 20080234792A1
• Time in Patent Office: 1,610 Days
• Field of Search: 607115-116, 607119-126
• US Class Current: 607/126
• CPC Class Codes: A61N 1/057 Anchoring means; Means for fixing the head inside the heart

Abstract

Some embodiments relate to a method of implanting a cardiac lead. An expansion module is implanted in a target region within vasculature, the target region being defined by a portion of a brachiocephalic vein and a portion of a corresponding subclavian vein. The expansion module is transitioned from a collapsed state to an expanded state within the target region to contact the vasculature. A cardiac lead is implanted through the expansion module, the cardiac lead defining an intermediate section corresponding to the target region. The intermediate section of the cardiac lead includes a surface treatment adapted to reduce at least one of cell proliferation, thrombosis, fibrosis, and inflammation at the target region.

Claims

1. A method of implanting a cardiac lead, the method comprising:

implanting an expansion module in a target region within vasculature, the target region being defined by a portion of a brachiocephalic vein and a portion of a corresponding subclavian vein;

transitioning the expansion module from a collapsed state to an expanded state within the target region to contact the vasculature; and

implanting a cardiac lead through the expansion module, the cardiac lead defining an intermediate section corresponding to the target region;

wherein the intermediate section of the cardiac lead includes a surface treatment adapted to reduce at least one of cell proliferation, thrombosis, fibrosis, and inflammation at the target region.

2. The method of claim 1, wherein the surface treatment of the intermediate section includes a non-eluting surface modification selected from the group consisting of:

a polyethylene-glycol surface modification, ethylene-glycol surface modification, a fluorinated hydrocarbon surface modification, a phosphorylcholine surface modification, a taurine surface modification, a sulfobetaine surface modification, a zwitterion-type surface modification, and combinations thereof.

3. The method of claim 1, wherein the surface treatment of the intermediate section includes an eluting coating of a therapeutic agent selected from the group consisting of:

paclitaxel-SIBS, salicylic acid based polyanhydrides, sirolimus, everolimus, doxorubicin, mitomycin, fluorodeoxyuridine, heparin, heparin derivatives, salicylic acid, salicylic acid polyahydrides, and combinations thereof.

4. The method of claim 1, wherein the expansion module includes at least one of an internal sleeve adapted to reduce cellular adhesion between the intermediate section of the cardiac lead and the vasculature and a surface modification adapted to reduce venous occlusion at the target region.

5. The method of claim 1, wherein the brachiocephalic, external jugular, and subclavian veins correspond to the left side of the body.

6. A method of implanting a cardiac lead prior to venous occlusion at a target region defined by a junction of a brachiocephalic vein and an external jugular vein, the method comprising:

implanting a first expansion member in a vascular pathway including the target region;

expanding the first expansion member to an expanded state in the target region; and

implanting a cardiac lead within the vascular pathway such that the cardiac lead extends through the target region and is received within the first expansion member, the cardiac lead including an insulator defining an outer surface of the cardiac lead;

wherein at least a portion of the outer surface of the cardiac lead extending through the target region includes a non-eluting surface modification including at least one of a polyethylene-glycol surface modification, an ethylene-glycol surface modification, a fluorinated hydrocarbon surface modification, a phosphorylcholine surface modification, a taurine surface modification, a sulfobetaine surface modification, and a zwitterion-type surface modification.

7. The method of claim 6, wherein at least one of the first and second expansion members includes an internal sleeve having a non-eluting surface modification.

8. The method of claim 7, wherein the internal sleeve is formed of ePTFE.

9. The method of claim 6, wherein the first expansion member further comprises an internal guide structure supporting the cardiac lead at a desired radial position within the first expansion member.